Sign in
Taking peoplePhase 1

Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults

Key facts

Who runs it
Sanaria Inc.
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
42 people, planned
Started
12 Mar 2026
Expected to end
30 Dec 2027
Type of study
Interventional, 8 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Normal Saline (Placebo)
  • PfSPZ-LARC2 Vaccine
  • PfSPZ Challenge (7G8)
Record updated
3 November 2026

Who can take part

Age
18 years to 45 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • Healthy adults (male or non-pregnant female) 18 to 45 years of age
  • Able and willing to participate for the duration of the study
  • Able and willing to provide written informed consent
  • Physical examination and laboratory results without clinically significant findings
  • Women of childbearing potential must agree to use effective means of birth control (e.g. oral or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) during the entire study
  • Due to the potential for reduced effectiveness of hormonal contraceptives during artemether and/or lumefantrine treatment, participants will be counseled to add an additional barrier method of contraception during treatment
  • Women with a history of surgical or chemical sterilization (e.g. tubal ligation, hysterectomy, other) must provide written documentation of the procedure from a health care provider
  • Agree not to travel to a malaria endemic region during the course of the trial

Who cannot take part

  • Receipt of a malaria vaccine in a prior clinical trial
  • Receipt of a live vaccine within 4 weeks of first immunization or of 3 or more non-live vaccines within 2 weeks of first immunization
  • Known allergy or hypersensitivity reaction (e.g., anaphylaxis, erythema multiforme or Stevens-Johnson syndrome, angioedema, vasculitis) to atovaquone-proguanil (Malarone®), artemether-lumefantrine (Coartem®), any components of these formulations, or any component of the investigational products
  • Participation in any study involving investigational vaccine or drug within 4 weeks prior to enrollment that in the estimation of the site PI might adversely affect the individual's safety or the quality of data to be collected
  • Plan to participate in another investigational vaccine/drug research during the study
  • Plan for major surgery between enrollment until 28 days post-CHMI
  • Use or planned use of any drug with anti-malarial activity that would precede or coincide with malaria challenge or vaccination
  • Anticipated use of medications known to cause drug reactions with atovaquone-proguanil or artemether-lumefantrine such as tetracycline, rifampin, rifabutin, cimetidine, metoclopramide, antacids, anti-coagulants such as coumarin, indinavir, and kaolin
  • History of a splenectomy or sickle cell disease
  • History of a neurologic disorder (including non-febrile seizures or complex febrile seizures) or formal history of migraine headache
  • History of anaphylaxis or other life-threatening reaction to a vaccine
  • Positive HIV, HBsAg or HCV serology
  • An abnormal electrocardiogram, defined as one showing pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm including isolated premature ventricular contractions, but excluding isolated premature atrial contractions; right or left bundle branch block; or advanced (secondary or tertiary) A-V heart block; or other clinically significant abnormalities on the electrocardiogram
  • History of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease
  • History of disturbances of the electrolyte balance (e.g., hypokalemia or hypomagnesemia)
  • History of chronic liver disease
  • Any medical, psychiatric, social, behavioral or occupational condition or situation (including active alcohol or drug abuse) that, in the judgment of the site PI, impairs the participant's ability to give informed consent, increases the risk to the participant of participation in the study, affects the ability of the participant to participate fully in the study, or might negatively impact the quality, consistency, integrity or interpretation of data derived from their participation in the study. This includes persons in emergency situations such as refugees
  • Evidence of increased cardiovascular disease risk; defined as >10% five-year risk by non-laboratory method (Gaziano, 2008) [80]
  • Anticipated use of medications known to:; Be substrates, inhibitors or strong inducers of CYP3A4 (e.g., rifampin, carbamazepine, phenytoin, and/or St. John's wort) [strong inducers of CYP3A4 when taken concomitantly with artemether and/or lumefantrine can result in decreased concentration(s) and loss of antimalarial efficacy]; Be metabolized by the cytochrome enzyme CYP2D6 (e.g., primaquine, tafenoquine, flecainide, imipramine, amitriptyline, clomipramine); Have a mixed effect on CYP3A4 (e.g., antiretrovirals); Prolong the QT interval (e.g., quinine, quinidine, halofantrine, mefloquine, procainamide, disopyramideamiodarone, sotalol, pimozide, ziprasidone, tetracycline, doxycline, fluoroquinolone, imidazole, and triazole antifungal agents). Note: in the case of halofantrine, this drug may not be used within a month of artemether/lumefantrine due to its very significant effect on QT interval
  • Family history (grandparents, parents or siblings) of congenital prolongation of the QT interval or sudden death
  • History of severe renal impairment (creatinine clearance <30 mL/min) (risk of pancytopenia in patients with severe renal impairment treated with proguanil)
  • Unable to provide informed consent including inability to pass the test of understanding
  • Current use of systemic immunosuppressant pharmacotherapy
  • Women who are breast-feeding, pregnant or planning to become pregnant during the study period
  • Any clinically significant deviation from the normal range in biochemistry or hematology tests measured at screening and not resolving

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 45 years old?

This trial is currently available in Germany.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) administered to healthy, malaria-naive study participants in Germany by direct venous inoculation (DVI) to determine safety, tolerability, and vaccine efficacy (VE) against controlled human malaria infection (CHMI). PfSPZ-LARC2 Vaccine contains a deletion of two genes, the Mei2 and LINUP genes, and undergoes developmental arrest in the late liver stages without releasing merozoites into the blood stream (blood stage parasites).

Read full original descriptionShow less

The primary objective of the study is to assess the safety and tolerability of administration of PfSPZ-LARC2 Vaccine, with special attention to the adequacy of attenuation, in the intention-to-treat (ITT) population.

The 8 groups in the trial

  • Part A-1 Main Cohort PfSPZ-LARC2 verum groupTreatment being tested

    The verum group (n=10) will receive three doses of 2x10\^5 PfSPZ of PfSPZ-LARC2 Vaccine by DVI on Days 1, 6 and 29. Participants will be followed up for parasitemia and adverse events after immunization. After immunizations on Day 1 (V1) and Day 6 (V2 = V1+5), qPCR and thick blood smears (TBS) will commence to monitor for P. falciparum blood stage infections. These will be done every other day from Day 7 (V1+6) to Day 23 (V1+22) and on Day 28 (V1+27), and then weekly thereafter until two weeks after the third immunization given at Day 29 (V1+28). Three weeks after the third immunization (V3), the 12 participants of Part A-1 (10 from verum and 2 from placebo) will undergo heterologous CHMI using DVI of 3.2x10\^3 PfSPZ Challenge (7G8).

    Treatment: PfSPZ-LARC2 Vaccine and PfSPZ Challenge (7G8)

  • Part A-1 Main Cohort Normal Saline control groupPlacebo, for comparison

    The blinded control group (n = 2) of the main cohort will receive normal saline as placebo, also by DVI. All of the participants in the main cohort will progress through a 3-dose immunization regimen of normal saline administered on Days 1, 6 and 29. Follow-up and CHMI will be same as A-1 Main Cohort verum group.

    Treatment: Normal Saline (Placebo) and PfSPZ Challenge (7G8)

  • Part A-2 Main Cohort PfSPZ-LARC2 verum groupTreatment being tested

    Two weeks after the last Part A-1 study participant has received the first vaccination (V1), vaccinations in Part A-2 (n=8, verum) will begin using the same dose and regimen as in Part A-1 main cohort verum group. The follow-up schedule will be identical to that in Part A-1 cohort. CHMI in the Part A-2 cohort will be initiated only after at least 14 days have elapsed since the last CHMI in Part A-1 and after confirmation that no CHMI-related SAEs have occurred in Part A-1. Heterologous CHMI dose via DVI will be the same as Part A-1 cohort.

    Treatment: PfSPZ-LARC2 Vaccine and PfSPZ Challenge (7G8)

  • Part A-2 Main Cohort Normal Saline control groupPlacebo, for comparison

    The blinded control group (n = 1) of the main cohort will receive normal saline as placebo by DVI on Days 1, 6 and 29. The follow-up schedule will be identical to that in Part A-1 cohort. CHMI in the Part A-2 cohort will be initiated only after at least 14 days have elapsed since the last CHMI in Part A-1 and after confirmation that no CHMI-related SAEs have occurred in Part A-1. Heterologous CHMI dose via DVI will be the same as Part A-1 cohort.

    Treatment: Normal Saline (Placebo)

  • Part B-1 Main Cohort PfSPZ-LARC2 verum groupTreatment being tested

    If any vaccinee in Part A develops Pf parasitemia following CHMI, the study will proceed to Part B. The verum group in the main cohort (n = 10) will receive 4x10\^5 PfSPZ of PfSPZ-LARC2 Vaccine per immunization dose by DVI on Days 1, 29, and 57. After the first vaccination V1, breakthrough monitoring will start on Day 6 and will be performed every second day until Day 21 and Day 28. After the second (V2) and third vaccination (V3), breakthrough monitoring will be performed at 7, 14, 21 and 27 days following each vaccination. Twelve weeks after the third immunization dose, the main cohort participants will undergo heterologous CHMI using DVI of 3.2x10\^3 PfSPZ of PfSPZ Challenge (7G8).

    Treatment: PfSPZ-LARC2 Vaccine and PfSPZ Challenge (7G8)

  • Part B-1 Main Cohort Normal Saline control groupPlacebo, for comparison

    The blinded control group (n = 2) of the main cohort will receive normal saline as placebo, also by DVI on Days 1, 29, and 57. Follow-up and CHMI will be same as B-1 Main Cohort verum group.

    Treatment: Normal Saline (Placebo) and PfSPZ Challenge (7G8)

  • Part B-2 Main Cohort PfSPZ-LARC2 verum groupTreatment being tested

    Two weeks after the last Part B-1 study participant has received the first vaccination (V1), vaccinations in Part B-2 (n=8, verum) will begin using the same dose and regimen as in Part B-1 main cohort verum group. The follow-up schedule will be identical to that in Part B-1 cohort. CHMI in the Part B-2 cohort will be initiated only after at least 14 days have elapsed since the last CHMI in Part B-1 and after confirmation that no CHMI-related SAEs have occurred in Part B-1. Heterologous CHMI dose via DVI will be the same as Part B-1 cohort.

    Treatment: PfSPZ-LARC2 Vaccine and PfSPZ Challenge (7G8)

  • Part B-2 Main Cohort Normal Saline control groupPlacebo, for comparison

    The blinded control group (n = 1) of the main cohort will receive normal saline as placebo, also by DVI on Days 1, 29, and 57. Follow-up and CHMI will be same as B-1 Main Cohort verum group.

    Treatment: Normal Saline (Placebo) and PfSPZ Challenge (7G8)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults
Criteria questions
Built from NCT06862453, who can take part
Record updated
3 November 2026